恩替卡韦-PLGA缓释微球的处方优化及体外释药研究
x

请在关注微信后,向客服人员索取文件

篇名: 恩替卡韦-PLGA缓释微球的处方优化及体外释药研究
TITLE:
摘要: 目的:优化恩替卡韦聚乳酸-羟基乙酸共聚物(PLGA)缓释微球的处方,并考察其体外释药特性。方法:采用乳化-溶剂挥发法制备恩替卡韦-PLGA缓释微球;以微球的包封率、载药量的综合评分为评价指标,设计正交试验优化投药量、药物-PLGA质量比、PLGA质量浓度、油相-水相体积比、聚乙烯醇(PVA)浓度,并进行验证试验;考察所制微球形态、粒径及体外释药情况(Q)。结果:最优处方为恩替卡韦20 mg、恩替卡韦-PLGA质量比1 ∶ 10、PLGA 质量浓度200 mg/ml、油相-水相体积比1 ∶ 10、PVA浓度2%。所制恩替卡韦-PLGA缓释微球的包封率为(86.52±3.25)%,载药量为(18.36±1.37)%,RSD均小于5.0%(n=3);其表面光滑圆整,平均粒径为58.35 μm;Q10 h、Q96 h、Q360 h分别为9.6%、42.9%、89.6%,体外释药符合Higuchi模型(r2=0.965 8)。结论:优化处方所制恩替卡韦-PLGA缓释微球的缓释性能良好。
ABSTRACT: OBJECTIVE: To optimize the formulation of entecavir PLGA sustained-release microspheres, and explore its drug release in vitro. METHODS: PLGA sustained-release microspheres was prepared by emulsification-solvent evaporation method. Using composite score of entrapment efficacy and drug loading as indexes, orthogonal test was designed to optimize drug amount, drug-PLGA mass ratio, PLGA mass concentration, oil phase-aqueous phase volume ratio and polyvinyl alcohol (PVA) concentration; and validation test was also conducted. The prepared microsphere morphology, particle size and durg release in vitro were detected. RESULTS: The optimized formulation was entecavir 20 mg, entecavir-PLGA mass ratio 1 ∶ 10, PLGA mass concentration 200 mg/ml, oil phase-aqueous phase volume ratio 1 ∶ 10, and PVA concentration 2%; entrapment efficacy was (86.52±3.25)%, drug loading was (18.36±1.37)%, RSDs were lower than 5.0% (n=3); it was round and smooth in appearance with average particle size of 58.35 μm; Q10 h, Q96 h and Q360 h were 9.6%, 42.9% and 89.6%, and the drug release in vitro fitted to Higuchi model (r2=0.965 8). CONCLUSIONS: Entecavir PLGA sustained-release microspheres prepared by optimized formulation has good sustained-release performance.
期刊: 2016年第27卷第25期
作者: 林凤云,罗易,何雄伟
AUTHORS: LIN Fengyun,LUO Yi,HE Xiongwei
关键字: 恩替卡韦;缓释微球;聚乳酸-羟基乙酸共聚物;体外释药;正交试验;制备;处方优化
KEYWORDS: Entecavir; Microspheres; PLGA; Drug release in vitro; Orthogonal test; Preparation; Formulation optimization
阅读数: 317 次
本月下载数: 8 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!